What question did this study set out to answer?

To assess the safety, antiviral efficacy, and symptom recovery outcomes of inhaled SNS812 in adults with mild-to-moderate COVID-19.

August 16, 2026Journal of Biomedical ScienceOpen Access

Safety and antiviral activity of inhaled siRNA SNS812 for treatment of mild-to-moderate COVID-19: a phase 2 randomized trial

View Full Paper

Ask AI

Bookmark

Authors

SCShey‐Ying ChenNational Taiwan University Hospital SCSui‐Yuan ChangNational Taiwan University YCYi-Chung ChangSimpson Biotech Company (Taiwan)

Discussion

Member takes

Overview

Randomized double-blind trial demonstrates safety and rapid viral clearance with inhaled siRNA SNS812 in mild-to-moderate COVID-19, indicating broad activity against immune-evasive variants.

Key Points

To assess the safety, antiviral efficacy, and symptom recovery outcomes of inhaled SNS812 in adults with mild-to-moderate COVID-19.
Conducted a phase 2, double-blind, randomized, placebo-controlled trial (NCT05941793) enrolling 135 adults within 3 days of COVID-19 symptom onset.
Participants were randomly assigned (1:1:1) to receive inhaled SNS812 at 100 mg, 200 mg, or placebo once daily for 7 days.
Safety served as the primary endpoint, with secondary endpoints evaluating time to sustained alleviation (TTSA) and resolution (TTSR) of target symptoms alongside exploratory virological outcomes.
No treatment-related adverse events or serious adverse events occurred across any study group.
SNS812 200 mg accelerated viral clearance compared to placebo, showing shorter median time to antigen negativity (2.9 vs 3.6 days; p = 0.007) and faster viral load reduction rate (-0.755 vs -0.652; p = 0.040).
SNS812 200 mg significantly improved symptom duration versus placebo, reducing median TTSR (6.1 vs 8.1 days; adjusted HR 2.07, 95% CI 1.30–3.29) and median TTSA (3.6 vs 6.5 days; adjusted HR 1.81, 95% CI 1.14–2.88).

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/6a817980f2fb91fc834acacc https://doi.org/10.1186/s12929-026-01284-5

View Full Paper

Ask AI

Bookmark

August 16, 2026Journal of Biomedical ScienceOpen Access

Safety and antiviral activity of inhaled siRNA SNS812 for treatment of mild-to-moderate COVID-19: a phase 2 randomized trial

View Full Paper

Ask AI

Bookmark

Authors

SCShey‐Ying ChenNational Taiwan University Hospital SCSui‐Yuan ChangNational Taiwan University YCYi-Chung ChangSimpson Biotech Company (Taiwan)

Discussion

Member takes

Overview

Randomized double-blind trial demonstrates safety and rapid viral clearance with inhaled siRNA SNS812 in mild-to-moderate COVID-19, indicating broad activity against immune-evasive variants.

Key Points

To assess the safety, antiviral efficacy, and symptom recovery outcomes of inhaled SNS812 in adults with mild-to-moderate COVID-19.
Conducted a phase 2, double-blind, randomized, placebo-controlled trial (NCT05941793) enrolling 135 adults within 3 days of COVID-19 symptom onset.
Participants were randomly assigned (1:1:1) to receive inhaled SNS812 at 100 mg, 200 mg, or placebo once daily for 7 days.
Safety served as the primary endpoint, with secondary endpoints evaluating time to sustained alleviation (TTSA) and resolution (TTSR) of target symptoms alongside exploratory virological outcomes.
No treatment-related adverse events or serious adverse events occurred across any study group.
SNS812 200 mg accelerated viral clearance compared to placebo, showing shorter median time to antigen negativity (2.9 vs 3.6 days; p = 0.007) and faster viral load reduction rate (-0.755 vs -0.652; p = 0.040).
SNS812 200 mg significantly improved symptom duration versus placebo, reducing median TTSR (6.1 vs 8.1 days; adjusted HR 2.07, 95% CI 1.30–3.29) and median TTSA (3.6 vs 6.5 days; adjusted HR 1.81, 95% CI 1.14–2.88).

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/6a817980f2fb91fc834acacc https://doi.org/10.1186/s12929-026-01284-5

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark